Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + cisplatin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Everolimus + cisplatin is a combination regimen used in oncology clinical trials for the treatment of various advanced cancers. Everolimus is an mTOR inhibitor that binds to FKBP-12 and inhibits the activation of mTOR (mechanistic target of rapamycin), leading to reduced cell proliferation, angiogenesis, and glucose uptake by blocking progression from G1 to S phase in the cell cycle and inducing apoptosis[1][3][5]. Cisplatin is a platinum-based chemotherapy agent that acts as an alkylating agent; it cross-links DNA at guanine bases causing DNA damage and triggering apoptosis through multiple signaling pathways including p53 activation[2][6]. The combination has been studied in diseases such as advanced neuroendocrine carcinoma (EP-NEC), urothelial bladder cancer, and small cell lung cancer[3][5][8].
- Brand names
- Platinol (cisplatin)Afinitor (everolimus)
- Other names
- everolimuscisplatincis-diamminedichloroplatinum(II)
02
Targets
DNAmTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on everolimus + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + cisplatin.